Can Papain-like Protease Inhibitors Halt SARS-CoV-2 Replication?

Overview

Journal ACS Pharmacol Transl Sci

Publisher American Chemical Society

Specialty Biochemistry

Date 2020 Oct 16

PMID 33062954

Citations 28

Authors

Biplab K Maiti

Affiliations

Soon will be listed here.

Abstract

SARS-CoV-2 encoded papain-like protease (PLpro) harbors a labile Zn site (Cys-X-X-Cys-X -Cys-X-Cys) and a classic catalytic site (Cys-His-Asp), which play key roles for viral replication and hence represent promising drug targets. In this Viewpoint, both sulfur-based drugs and peptides-based inhibitors may block Cys residues in the catalytic and/or Zn site of CoV-2-PLpro, leading to dysfunction of CoV-2-PLpro and thereby halting viral replication.

Citing Articles

Analysis of Structures of SARS-CoV-2 Papain-like Protease Bound with Ligands Unveils Structural Features for Inhibiting the Enzyme.

Varghese A, Liu J, Liu B, Guo W, Dong F, Patterson T Molecules. 2025; 30(3).

PMID: 39942596 PMC: 11820935. DOI: 10.3390/molecules30030491.

Advances in the Search for SARS-CoV-2 M and PL Inhibitors.

Diogo M, Cabral A, de Oliveira R Pathogens. 2024; 13(10).

PMID: 39452697 PMC: 11510351. DOI: 10.3390/pathogens13100825.

Native Mass Spectrometry Reveals Binding Interactions of SARS-CoV-2 PLpro with Inhibitors and Cellular Targets.

James V, Godula R, Perez J, Beckham J, Butalewicz J, Sipe S ACS Infect Dis. 2024; 10(10):3597-3606.

PMID: 39303064 PMC: 11533220. DOI: 10.1021/acsinfecdis.4c00444.

Coordination chemistry suggests that independently observed benefits of metformin and Zn against COVID-19 are not independent.

Lockwood T Biometals. 2024; 37(4):983-1022.

PMID: 38578560 PMC: 11255062. DOI: 10.1007/s10534-024-00590-5.

Selenium-More than Just a Fortuitous Sulfur Substitute in Redox Biology.

Maia L, Maiti B, Moura I, Moura J Molecules. 2024; 29(1).

PMID: 38202704 PMC: 10779653. DOI: 10.3390/molecules29010120.

References

Garg D, Torbett B . Advances in targeting nucleocapsid-nucleic acid interactions in HIV-1 therapy. Virus Res. 2014; 193:135-43. PMC: 4252855. DOI: 10.1016/j.virusres.2014.07.004. View

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199-1207. PMC: 7121484. DOI: 10.1056/NEJMoa2001316. View

Poreba M, Salvesen G, Drag M . Synthesis of a HyCoSuL peptide substrate library to dissect protease substrate specificity. Nat Protoc. 2017; 12(10):2189-2214. DOI: 10.1038/nprot.2017.091. View

Baez-Santos Y, St John S, Mesecar A . The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res. 2015; 115:21-38. PMC: 5896749. DOI: 10.1016/j.antiviral.2014.12.015. View

Swaim C, Dwivedi V, Perng Y, Zhao X, Canadeo L, Harastani H . 6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro. iScience. 2021; 24(10):103213. PMC: 8487320. DOI: 10.1016/j.isci.2021.103213. View

Sargsyan K, Lin C, Chen T, Grauffel C, Chen Y, Yang W . Multi-targeting of functional cysteines in multiple conserved SARS-CoV-2 domains by clinically safe Zn-ejectors. Chem Sci. 2021; 11(36):9904-9909. PMC: 8162115. DOI: 10.1039/d0sc02646h. View

Lee Y, Wang Y, Duh Y, Yuan H, Lim C . Identification of labile Zn sites in drug-target proteins. J Am Chem Soc. 2013; 135(38):14028-31. DOI: 10.1021/ja406300c. View

Anand K, Ziebuhr J, Wadhwani P, Mesters J, Hilgenfeld R . Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 2003; 300(5626):1763-7. DOI: 10.1126/science.1085658. View

Rothan H, Stone S, Natekar J, Kumari P, Arora K, Kumar M . The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells. Virology. 2020; 547:7-11. PMC: 7236683. DOI: 10.1016/j.virol.2020.05.002. View

10.

Lin M, Moses D, Hsieh C, Cheng S, Chen Y, Sun C . Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes. Antiviral Res. 2018; 150:155-163. PMC: 7113793. DOI: 10.1016/j.antiviral.2017.12.015. View

11.

Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S . Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020; 581(7807):215-220. DOI: 10.1038/s41586-020-2180-5. View

12.

Rut W, Lv Z, Zmudzinski M, Patchett S, Nayak D, Snipas S . Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design. Sci Adv. 2020; 6(42). PMC: 7567588. DOI: 10.1126/sciadv.abd4596. View

13.

Xu J, Zhao S, Teng T, Abdalla A, Zhu W, Xie L . Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses. 2020; 12(2). PMC: 7077191. DOI: 10.3390/v12020244. View

14.

Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H . Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020; 581(7807):221-224. PMC: 7328981. DOI: 10.1038/s41586-020-2179-y. View